埃拉瓦环素:数据基于真实的证据
Simone Giuliano1,2, Luca Martini3,2, Francesca Prataviera4,2
1Department of Medicine.
The new microbiologica
|October 22, 2025
概括
埃拉瓦环素在治疗由多药耐药细菌引起的复杂感染方面表现有前途. 这项现实研究发现临床治愈率为69.2%,但在一些患者中发现死亡率和不良事件更高.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 埃拉瓦环素是一种新型合成环素,具有针对多药耐药 (MDR) 细菌的广泛活性.
- 它是为了克服四环素耐药机制而设计的,在体外显示出对抗抗卡巴耐药 Enterobacterales 和 Acinetobacter baumannii 等病原体的有效性.
研究的目的:
- 评估eravacycline在患有复杂感染的住院患者的实际有效性和结果.
- 评估临床治愈率,死亡率和与临床环境中埃拉瓦环素使用相关的不良事件.
主要方法:
- 在2023年4月至2024年8月期间,对13名住院患者进行了回顾性研究,这些患者因复杂感染而接受了埃拉瓦环素治疗.
- 收集的数据包括患者人口统计数据,感染特征,微生物学概况,抗生素治疗方案和临床结果.
主要成果:
- 观察到的临床治愈率为69.2%.
- 死亡率为38.5%,在非幸存者中发现了抵抗机制和不充分的源控制.
- 大多数患者接受了组合治疗,主要是用β-乳糖胺,并注意到一种疑似药物诱导的肝毒性病例.
结论:
- 现实世界的数据表明,埃拉瓦环素在治疗MDR感染方面是有效的,与之前的发现保持一致.
- 限制包括小样本大小和回顾性设计,需要进一步的受控研究来确定其在复杂感染中的作用,而不仅仅是复杂的腹内感染 (cIAI).
关键词:
时代是埃瓦环素的时代VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM VIM Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim Vim血流感染 感染 感染美国中央情报局更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.7K
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
738
相关概念视频
01:13Bioequivalence studies: Biowaivers
220
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
220
01:28Antimicrobial Effectiveness
898
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
898
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
01:15Renal Drug Excretion: Overview
646
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
646
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
207
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
207